Clinical trial readout dates for Nurix Therapeutics Inc., compiled from
ClinicalTrials.gov, alongside the SEC filings where results are announced.
The next expected readout is January 2028.
Next readoutJanuary 2028in ~14 months
Upcoming readouts31 Phase 3
Market cap$2.4B
Cash & investments$1.10Bas of Aug 31, 2026
Recent 8-K filings1latest 2026-11-03
Upcoming readouts
Phase 2NX-5948
Chronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma (SLL) · NCT07221500
Nurix Therapeutics Inc. reported $1.10B in cash, cash equivalents and marketable securities at Aug 31, 2026 (10-Q filed 2026-10-13). It reported net income of $550M for that quarter.